A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
Inclusion Criteria:
Subject must be at least 18 years of age.
Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.
Subjects with moderately to severely active UC based on Mayo score criteria.
Subjects must have failed or be intolerant of at least one of the following treatments for UC:
Exclusion Criteria:
Torrance, California 90502, United States
Nashville, Tennessee 37212-1610, United States
Richmond, Virginia 23298, United States
Edmonton, Alberta T6G 2B7, Canada
Budapest, 1125, Hungary
Budapest, H-1076, Hungary
Debrecen, 4032, Hungary
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
Bucharest, Sector 5 cod 050098, Romania
Jud. Mures, 540103, Romania
Moscow, Russia 121309, Russia
Moscow, 129110, Russia
Novosibirsk, 630117, Russia
Yaroslavl, 150062, Russia
Bratislava, 831 04, Slovakia
Claremont, Cape Town, Western Cape 7708, South Africa
Dnipropetrovsk, 49074, Ukraine
Kharkiv, 61037, Ukraine